Search

Search Results

• OC07 | LONG-TERM COMBINATION WITH ONABOTULINUMTOXINA AND ATOGEPANT TO ACHIEVE HIGHER STANDARDS OF MIGRAINE CONTROL: A 52-WEEK, PROSPECTIVE, REAL-WORLD EVALUATION (SYNERGY STUDY)

  L. Francesco Iannone¹, M. Romozzi^2|3, A. Russo⁴, I. Finkelstein⁵, D. Seabi⁶, A. Ahlden⁶, A. Hege Aamodt^7|8|9, P. Calabresi^2|3, C. Vollono³, E. Caronna^10|11, P. Pozo-Rosich^10|11, E. Andreas Tronvik^8|12|13, C. Sundal^6|12 | ¹Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy; ²Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; ³Neurologia, Dipartimento di neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; ⁴Inter-departmental Program of Headache Medicine and Primary Pain Syndromes, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy; ⁵Toronto Headache and Pain clinic; Pain Clinic, Toronto, Canada; ⁶NeuroClinicNorway, Lillestrøm, Norway; ⁷Department of Neurology, Oslo University Hospital, Rikshospitalet, Norway; ⁸NorHead, Norwegian Headache Research Centre; NTNU, Norwegian University of Science and Technology, Trondheim, Norway; ⁹Institute of Population Health, Faculty of Health and Life Sciences, University of Liverpool, UK; ¹⁰Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Neuroscience, Universitat Autònoma de Barcelona, Spain; ¹¹Headache Clinic, Neurology Department, Vall d’Hebron Hospital, Barcelona, Spain; ¹²Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway; ¹³Neuroclinic, St. Olavs Hospital, Trondheim, Norway

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.15945

  • 0 abstract views
  • 0 PDF